WuXi PharmaTech Set For Expansion With Production of Intermediate For New Vertex Hepatitis Drug
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Although WuXi PharmaTech's planned merger with Charles River Labs was abandoned at the last moment in mid-2010 due to shareholder resistance to the union, the Shanghai-based contract research organization is on track to post solid earnings this year and next, according to a prominent analyst who closely follows China's healthcare sector